Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)

Daniel A Sussman, Nisa Kubiliun, Parvez M. Mulani, Jingdong Chao, Carol A T Gillis, Mei Yang, Mei Lu, Maria T Abreu

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Anti-tumor necrosis factor (TNF) medications have similar efficacy in Crohn's disease (CD), but have not been compared in the real world. This study compared health costs and utilization for patients with CD newly initiating anti-TNF therapy with adalimumab (ADA) or infliximab (IFX) by using insurance data. Methods: CD patients initiating ADA or IFX therapy were identified from the MarketScan database. ADA and IFX groups were matched using a propensity score. The primary endpoint was direct costs of healthcare for the 6 months following initiation. The secondary endpoints compared healthcare utilization between groups. Results: After propensity matching, characteristics were similar between the ADA (n = 623) and IFX (n = 623) groups. During the 6-month interval following anti-TNF initiation, healthcare costs were significantly lower for ADA compared with IFX. Total healthcare cost was $18,885 for ADA and $24,355 for IFX, a difference in cost of $5,470 (P < 0.0001). CD-related costs made up the majority of the costs: $16,454 for ADA and $22,316 for IFX (P < 0.0001). The largest difference in cost was seen in outpatient visits: $2,082 difference between the two groups (P < 0.0001). Both all-cause and CD-related hospitalization decreased for both ADA and IFX groups. Emergency room and hospitalization use in the 6-month follow-up period was not statistically different between groups, although numerically slightly higher in the IFX group. Conclusions: Patients with CD using ADA had lower healthcare costs than patients using IFX; this difference was partly driven by outpatient medical costs. (Inflamm Bowel Dis 2012;)

Original languageEnglish
Pages (from-to)2043-2055
Number of pages13
JournalInflammatory Bowel Diseases
Volume18
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Retrospective Studies
Costs and Cost Analysis
Crohn Disease
Health Care Costs
Tumor Necrosis Factor-alpha
Hospitalization
Outpatients
Adalimumab
Infliximab
Propensity Score
Cost of Illness
Insurance
Hospital Emergency Service
Research Design
Databases
Delivery of Health Care
Therapeutics

Keywords

  • adalimumab
  • Crohn's disease
  • healthcare costs
  • infliximab

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Comparison of medical costs among patients using adalimumab and infliximab : A retrospective study (COMPAIRS). / Sussman, Daniel A; Kubiliun, Nisa; Mulani, Parvez M.; Chao, Jingdong; Gillis, Carol A T; Yang, Mei; Lu, Mei; Abreu, Maria T.

In: Inflammatory Bowel Diseases, Vol. 18, No. 11, 01.11.2012, p. 2043-2055.

Research output: Contribution to journalArticle

Sussman, Daniel A ; Kubiliun, Nisa ; Mulani, Parvez M. ; Chao, Jingdong ; Gillis, Carol A T ; Yang, Mei ; Lu, Mei ; Abreu, Maria T. / Comparison of medical costs among patients using adalimumab and infliximab : A retrospective study (COMPAIRS). In: Inflammatory Bowel Diseases. 2012 ; Vol. 18, No. 11. pp. 2043-2055.
@article{7f56551178254eb3b6f5f6431d0c00a5,
title = "Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)",
abstract = "Background: Anti-tumor necrosis factor (TNF) medications have similar efficacy in Crohn's disease (CD), but have not been compared in the real world. This study compared health costs and utilization for patients with CD newly initiating anti-TNF therapy with adalimumab (ADA) or infliximab (IFX) by using insurance data. Methods: CD patients initiating ADA or IFX therapy were identified from the MarketScan database. ADA and IFX groups were matched using a propensity score. The primary endpoint was direct costs of healthcare for the 6 months following initiation. The secondary endpoints compared healthcare utilization between groups. Results: After propensity matching, characteristics were similar between the ADA (n = 623) and IFX (n = 623) groups. During the 6-month interval following anti-TNF initiation, healthcare costs were significantly lower for ADA compared with IFX. Total healthcare cost was $18,885 for ADA and $24,355 for IFX, a difference in cost of $5,470 (P < 0.0001). CD-related costs made up the majority of the costs: $16,454 for ADA and $22,316 for IFX (P < 0.0001). The largest difference in cost was seen in outpatient visits: $2,082 difference between the two groups (P < 0.0001). Both all-cause and CD-related hospitalization decreased for both ADA and IFX groups. Emergency room and hospitalization use in the 6-month follow-up period was not statistically different between groups, although numerically slightly higher in the IFX group. Conclusions: Patients with CD using ADA had lower healthcare costs than patients using IFX; this difference was partly driven by outpatient medical costs. (Inflamm Bowel Dis 2012;)",
keywords = "adalimumab, Crohn's disease, healthcare costs, infliximab",
author = "Sussman, {Daniel A} and Nisa Kubiliun and Mulani, {Parvez M.} and Jingdong Chao and Gillis, {Carol A T} and Mei Yang and Mei Lu and Abreu, {Maria T}",
year = "2012",
month = "11",
day = "1",
doi = "10.1002/ibd.22873",
language = "English",
volume = "18",
pages = "2043--2055",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Comparison of medical costs among patients using adalimumab and infliximab

T2 - A retrospective study (COMPAIRS)

AU - Sussman, Daniel A

AU - Kubiliun, Nisa

AU - Mulani, Parvez M.

AU - Chao, Jingdong

AU - Gillis, Carol A T

AU - Yang, Mei

AU - Lu, Mei

AU - Abreu, Maria T

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Background: Anti-tumor necrosis factor (TNF) medications have similar efficacy in Crohn's disease (CD), but have not been compared in the real world. This study compared health costs and utilization for patients with CD newly initiating anti-TNF therapy with adalimumab (ADA) or infliximab (IFX) by using insurance data. Methods: CD patients initiating ADA or IFX therapy were identified from the MarketScan database. ADA and IFX groups were matched using a propensity score. The primary endpoint was direct costs of healthcare for the 6 months following initiation. The secondary endpoints compared healthcare utilization between groups. Results: After propensity matching, characteristics were similar between the ADA (n = 623) and IFX (n = 623) groups. During the 6-month interval following anti-TNF initiation, healthcare costs were significantly lower for ADA compared with IFX. Total healthcare cost was $18,885 for ADA and $24,355 for IFX, a difference in cost of $5,470 (P < 0.0001). CD-related costs made up the majority of the costs: $16,454 for ADA and $22,316 for IFX (P < 0.0001). The largest difference in cost was seen in outpatient visits: $2,082 difference between the two groups (P < 0.0001). Both all-cause and CD-related hospitalization decreased for both ADA and IFX groups. Emergency room and hospitalization use in the 6-month follow-up period was not statistically different between groups, although numerically slightly higher in the IFX group. Conclusions: Patients with CD using ADA had lower healthcare costs than patients using IFX; this difference was partly driven by outpatient medical costs. (Inflamm Bowel Dis 2012;)

AB - Background: Anti-tumor necrosis factor (TNF) medications have similar efficacy in Crohn's disease (CD), but have not been compared in the real world. This study compared health costs and utilization for patients with CD newly initiating anti-TNF therapy with adalimumab (ADA) or infliximab (IFX) by using insurance data. Methods: CD patients initiating ADA or IFX therapy were identified from the MarketScan database. ADA and IFX groups were matched using a propensity score. The primary endpoint was direct costs of healthcare for the 6 months following initiation. The secondary endpoints compared healthcare utilization between groups. Results: After propensity matching, characteristics were similar between the ADA (n = 623) and IFX (n = 623) groups. During the 6-month interval following anti-TNF initiation, healthcare costs were significantly lower for ADA compared with IFX. Total healthcare cost was $18,885 for ADA and $24,355 for IFX, a difference in cost of $5,470 (P < 0.0001). CD-related costs made up the majority of the costs: $16,454 for ADA and $22,316 for IFX (P < 0.0001). The largest difference in cost was seen in outpatient visits: $2,082 difference between the two groups (P < 0.0001). Both all-cause and CD-related hospitalization decreased for both ADA and IFX groups. Emergency room and hospitalization use in the 6-month follow-up period was not statistically different between groups, although numerically slightly higher in the IFX group. Conclusions: Patients with CD using ADA had lower healthcare costs than patients using IFX; this difference was partly driven by outpatient medical costs. (Inflamm Bowel Dis 2012;)

KW - adalimumab

KW - Crohn's disease

KW - healthcare costs

KW - infliximab

UR - http://www.scopus.com/inward/record.url?scp=84867579461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867579461&partnerID=8YFLogxK

U2 - 10.1002/ibd.22873

DO - 10.1002/ibd.22873

M3 - Article

C2 - 22241679

AN - SCOPUS:84867579461

VL - 18

SP - 2043

EP - 2055

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 11

ER -